Literature DB >> 16354557

Prevalence and evolution of drug resistance HIV-1 variants in Henan, China.

Jing Yun Li1, Han Ping Li, Lin Li, Hong Li, Zhe Wang, Kun Yang, Zuo Yi Bao, Dao Min Zhuang, Si Yang Liu, Yong Jian Liu, Hui Xing, Yi Ming Shao.   

Abstract

To understand the prevalence and evolution of drug resistant HIV strains in Henan China after the implementation of free antiretroviral therapy for AIDS patients. 45 drug naïve AIDS patients, 118 AIDS patients who received three months antiretroviral therapy and 124 AIDS patients who received six months antiretroviral treatment were recruited in the southern part of Henan province. Information on general condition, antiretroviral medicines, adherence and clinical syndromes were collected by face to face interview. Meanwhile, 14 ml EDTA anticoagulant blood was drawn. CD4/CD8 T cell count, viral load and genotypic drug resistance were tested. The rates of clinical improvement were 55.1% and 50.8% respectively three months and six months after antiretroviral therapy. The mean CD4 cell count after antiretroviral therapy was significantly higher than in drug naïve patients. The prevalence rate of drug resistant HIV strains were 13.9%, 45.4% and 62.7% in drug naïve patients, three month treatment patients and six month treatment patients, respectively. The number of resistance mutation codons and the frequency of mutations increased significantly with continued antiretroviral therapy. The mutation sites were primarily at the 103, 106 and 215 codons in the three-month treatment group and they increased to 15 codon mutations in the six-month treatment group. From this result, the evolution of drug resistant strains was inferred to begin with the high level NNRTI resistant strain, and then develop low level resistant strains to NRTIs. The HIV strains with high level resistance to NVP and low level resistance to AZT and DDI were highly prevalent because of the AZT+DDI+NVP combination therapy. These HIV strains were also cross resistant to DLV, EFV, DDC and D4T. Poor adherence to therapy was believed to be the main reason for the emergence and prevalence of drug resistant HIV strains. The prevalence of drug resistant HIV strains was increased with the continuation of antiretroviral therapy in the southern part of Henan province. Measures, that could promote high level adherence, provide new drugs and change ART regimens in failing patients, should be implemented as soon as possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354557     DOI: 10.1038/sj.cr.7290356

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  15 in total

1.  HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China.

Authors:  Wang Lu; Ge Zeng; Jing Luo; Shan Duo; Gao Xing; Ding Guo-Wei; Zhou Jian-Ping; He Wen-Sheng; Wang Ning
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10-01       Impact factor: 3.731

2.  Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.

Authors:  Sihong Xu; Ping Zhong; Jingyun Li; Aijing Song; Hanping Li; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

3.  Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China.

Authors:  Minqi Luo; Huan Liu; Ke Zhuang; Li Liu; Bo Su; Rongrong Yang; Po Tien; Linqi Zhang; Xien Gui; Zhiwei Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

4.  Cultural adaptation of an evidence-based nursing intervention to improve medication adherence among people living with HIV/AIDS (PLWHA) in China.

Authors:  Ann B Williams; Honghong Wang; Jane Burgess; Xianhong Li; Karina Danvers
Journal:  Int J Nurs Stud       Date:  2012-09-13       Impact factor: 5.837

5.  Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV type 1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China.

Authors:  Changfu Yang; Shuyuan Liu; Taisong Zhang; Yaping Hou; Xiaoli Liu; Yun Gao; Guang Yang; Zhen Wang; Huayun Chen; Ming Li; Zhenyu Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-12       Impact factor: 2.205

6.  ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort.

Authors:  Peng Zhu; Qian Zhu; Yilei Zhang; Xuejun Ma; Zizhao Li; Jie Li; Jiazhong Chen; Le Luo; Huijun Z Ring; Brian Z Ring; Li Su
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

7.  Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China.

Authors:  Min Chen; Yanling Ma; Song Duan; Hui Xing; Shitang Yao; Yingzhen Su; Hongbing Luo; Li Yang; Huichao Chen; Liru Fu; Aijuan Qu; Chin-Yih Ou; Manhong Jia; Lin Lu
Journal:  BMC Infect Dis       Date:  2012-12-28       Impact factor: 3.090

8.  Low prevalence of the transmitted HIV-1 drug resistance among newly diagnosed HIV-1 individuals in Jiangsu Province, China during 2009-2011.

Authors:  Hongxiong Guo; Xiaoqin Xu; Haiyang Hu; Ying Zhou; Haitao Yang; Tao Qiu; Gengfeng Fu; Xiping Huan
Journal:  BMC Public Health       Date:  2015-02-10       Impact factor: 3.295

9.  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

Authors:  Hanping Li; Min Zhong; Wei Guo; Daomin Zhuang; Lin Li; Yongjian Liu; Zuoyi Bao; Siyang Liu; Xiaolin Wang; Tianyi Li; Shaomin Yang; Jingyun Li
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

10.  Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.

Authors:  Yi Bao; Di Tian; Ying-Ying Zheng; Hong-Li Xi; Dan Liu; Min Yu; Xiao-Yuan Xu
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.